Clinical efficacy of bevacizumab combined with afatinib in the treatment of non-small cell lung cancer

Objective:To investigate the clinical efficacy of bevacizumab combined with afatinib in the treatment of non-small cell lung cancer.Methods: Ninety-eight patients with non-small cell lung cancer admitted to our hospital from December 2015 to December 2017 were randomly divided into the control group (49 cases) and the experimental group (49 cases). The group was treated with conventional first-line chemotherapy (pemetrexed plus carboplatin). The experimental group was treated with bevacizumab plus afatinib. The therapeutic effects of the two groups were observed. Immune function, angiogenesis related indicators and incidence of adverse reactions.Results: The levels of CD3+, CD4+, CD4+/CD8+, IgG, IgM, IgA, VEGF, BFGF and HDGF were not significantly different between the two groups. After treatment, both groups were reduced, and the experimental group CD3+, CD4+, The levels of CD4+/CD8+, IgG, IgM and IgA were significantly higher than those of the control group. The levels of VEGF, BFGF and HDGF were significantly lower than those of the control group. The effective rate of the experimental group was significantly higher than that of the control group. There was no significant difference in the rate.Conclusion: Bevacizumab combined with afatinib can effectively improve the therapeutic effect of patients with non-small cell lung cancer. It has been the expression of angiogenic factors, improve the immune function of patients and increase the adverse reactions of patients, which is worthy of clinical promotion.